Blair William & Co. IL Sells 788 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Blair William & Co. IL lessened its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 54,382 shares of the company’s stock after selling 788 shares during the period. Blair William & Co. IL owned about 0.11% of Axsome Therapeutics worth $4,601,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AXSM. FMR LLC raised its stake in shares of Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after purchasing an additional 185,951 shares in the last quarter. Geode Capital Management LLC increased its holdings in Axsome Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock worth $81,659,000 after buying an additional 23,564 shares during the last quarter. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 1.1% in the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after acquiring an additional 8,125 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Axsome Therapeutics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock valued at $27,755,000 after acquiring an additional 5,438 shares during the last quarter. Finally, Iron Triangle Partners LP acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth about $22,671,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AXSM shares. Royal Bank of Canada raised their target price on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Truist Financial raised their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Axsome Therapeutics in a report on Thursday, March 6th. Robert W. Baird raised their price target on Axsome Therapeutics from $132.00 to $160.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. Finally, Mizuho lifted their price objective on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an “outperform” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $167.64.

Axsome Therapeutics Stock Down 2.7 %

NASDAQ AXSM opened at $118.53 on Monday. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The company has a market cap of $5.78 billion, a price-to-earnings ratio of -19.79 and a beta of 1.00. The company has a 50 day moving average of $119.67 and a 200-day moving average of $101.22. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.